Nucleated cells were quantified using the pocH-100i device (Sysmex, Villepinte, France). Cell viability was analyzed by flow cytometry using 7-aminoActinomycin D. CD3+ and CD14+ cells were quantified by FACS analysis, only in the Nancy center.
In both centers, the same treatment regimen was used with at least 3 ECP (fresh or 'cryo-ECP') per week for acute GvHD, and 1 or 2 ECP per week (depending on GvHD grade) for chronic or late acute GVHD, until clinical improvement.
The clinical severity of acute GvHD was determined as defined in the 1994 consensus conference criteria. 5 The severity of chronic GvHD was determined as per the 2005 National Institutes of Health (NIH) consensus guidelines. 6 Response was retrospectively assessed at 1, 3 and 6 months in all patients. Clinical CR was defined as GvHD disappearance, PR as a GvHD grade regression and no remission (No R) as a GvHD progression on ECP treatment.
For each patient, 3 series corresponding to either 'total fresh', 'divided fresh' or 'thawed' treated WBC were distinguished. The mean of all series was analyzed using the non-parametric Wilcoxon test. The correlation between variables was analyzed using the non-parametric Spearman test. Statistical significance was set for a P-value o 0.05.
From 2009 to 2015, 231 'cryo-ECP' (including 83 in Nancy Hospital and 148 in CF Hospital) were performed in 20 patients including 10 males. Thirteen patients (8 children) were treated for acute GvHD (Patients 1-13). Seven patients (5 children) were treated for chronic GvHD (patients 14-20, Table 1 ). Skin was involved in 15 patients.
Indications for FTWBC infusions were venous access failure (n = 8), bacterial infections (n = 6), very poor medical condition (n = 3), deep cytopenia (n = 6), bad compliance (n = 1) and patients living too far away from the HSCT center (n = 4) whose treated cells were transported to a hospital near their home ( Table 1 ). The median number of 'classic fresh' ECP before first cryopreservation was of 5 (0-85) sessions. The 20 patients received a median number of 8.5 FTWBC infusions (1-36), corresponding to a median rate of 30% (1-69%) of cryo-ECP ( Table 2 ). The median time between cryopreservation and reinfusion was of 11.5 (1-116) days. 'Split' sessions (either thawed or fresh) represented a median proportion of 68% of the total number of ECP sessions (2-100%).
No adverse event occurred after the 231 FTWBC infusions. The mean number of FTWBC infused to each patient was of 26.2 × 10 6 WBC/kg (±21.6), versus 33.6 × 10 6 WBC/kg (±24.7) for fresh cells after cell product division (P = 0.008), and versus 56.2 × 10 6 WBC/kg (±44.9) for total fresh cells (conventional off-line ECP; P = 0.003).
The mean WBC viability was of 98% ± 1.5% versus 84% ± 8.7% for fresh and thawed cells after UVA-irradiation, respectively (P = 0.003). The mean number of CD3+ and CD14+ cells infused in to each patient in Nancy center was similar before and after cryopreservation: 8.5 × 10 6 CD3+ cells/kg (±14.0) for FTWBC, versus 10.4 × 10 6 CD3+ cells/kg (±14.1) for fresh cells after cell product division (P = 0.515); 7.1 × 10 6 CD14+ cells/kg (±8.6) for FTWBC versus 6.5 × 10 6 CD14+ cells/kg (±6.5) for fresh divided cells (P = 0.260). The mean viability of treated CD3+ cells after cryopreservation was 92% ± 9.3%.
We observed a significant correlation between the circulating monocyte and lymphocyte counts and the mean number of thawed CD14+ cells (P = 0.019), and thawed CD3+ cells (P = 0.002) reinfused to the patient, respectively.
'Cryo-ECP' was the only way to perform ECP in 13 patients, and it allowed treatment intensity to be maintained in the seven others. Transfusions were avoided each time FTWBC were reinfused in six patients who experienced deep cytopenia. Moreover, FTWBC were transported to other care centers for four patients so that treatment was feasible.
The mean follow-up duration was 21 months. Six patients died from 2 infections, 3 GvHD complications and 1 leukemia relapse. At 1 month (3 months) for acute (chronic) GvHD, overall response was of 85%, including CR only for 25% of the 20 patients. At 6 months, overall response was achieved in 70% of patients who were still alive, including CR for 47% and PR for 23% of the 17 patients. (Table 2) . Among these patients, only one patient with PR received further immunosuppressive drugs. Steroids could be withdrawn in 10 patients before last ECP session. When focusing on the 11 patients who received more than 30% of 'cryo-ECP', the overall response rate was of 64% at 6 months (45% CR and 18% PR). Patients with lower grade acute GvHD showed a better response to ECP than those with higher grade acute GvHD.
The mechanism by which ECP induces immune tolerance has still not been fully elucidated: it may be assumed that apoptosis is induced in lymphocytes and monocytes, immunosuppressive cytokines are produced, and that tolerogenic APCs and regulatory T-cells are generated. 2 Merlin et al. 4 have shown that prior cryopreservation did not prevent in vitro ECP-induced lymphocyte apoptosis nor the inhibition of PHA-induced lymphocyte proliferation and of allogeneic lymphoid reaction.
Dividing the collected cell product implies a significant decrease by 54% in mean number of infused WBC, including 21% due to the cryopreservation itself. As the effects of ECP could be related to the activation of regulatory T cells rather than the direct induction of lymphocyte apoptosis, 7 the number of WBC would not play a major role. This hypothesis, which has been recently confirmed by a large single-center study, 8 led Hackstein et al. testing the concept of miniphotopheresis. 9 They obtained a mean dose of 10.4 × 10 6 UVA-irradiated WBC/kg per procedure, which is more than twice lower than our result. Abbreviations: CyA = cyclosporin A; ECP = extracorporeal photopheresis; MD = missing data; MMF = mycophenolate mofetil. a Acute GvHD is graded according to the Glücksberg classification, 5 and chronic GvHD is classified following NIH recommendations. 6 In our experience, the clinical response was similar to that usually described with ECP in adults and children with acute or chronic GvHD. 10, 11 Obviously, the efficacy of FTWBC infusions themselves could not be proved, because each patient also received conventional ECP during treatment. However, cryo-ECP was the only way to perform sustained ECP regimen in 13 patients. Thus, it should be assessed as a therapeutic option in further larger prospective studies of ECP.
